ARCT
Price
$9.48
Change
-$0.72 (-7.06%)
Updated
Apr 3 closing price
Capitalization
257.23M
38 days until earnings call
IMMP
Price
$1.61
Change
-$0.06 (-3.59%)
Updated
Apr 3 closing price
Capitalization
238.01M
54 days until earnings call
Ad is loading...

ARCT vs IMMP

Header iconARCT vs IMMP Comparison
Open Charts ARCT vs IMMPBanner chart's image
Arcturus Therapeutics Holdings
Price$9.48
Change-$0.72 (-7.06%)
Volume$362.42K
Capitalization257.23M
Immutep
Price$1.61
Change-$0.06 (-3.59%)
Volume$174.48K
Capitalization238.01M
ARCT vs IMMP Comparison Chart
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. IMMP commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and IMMP is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ARCT: $9.48 vs. IMMP: $1.61)
Brand notoriety: ARCT and IMMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 83% vs. IMMP: 233%
Market capitalization -- ARCT: $257.23M vs. IMMP: $238.01M
ARCT [@Biotechnology] is valued at $257.23M. IMMP’s [@Biotechnology] market capitalization is $238.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileIMMP’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • IMMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than IMMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while IMMP’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • IMMP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ARCT and IMMP are a good buy in the short-term.

Price Growth

ARCT (@Biotechnology) experienced а -20.96% price change this week, while IMMP (@Biotechnology) price change was -11.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

ARCT is expected to report earnings on May 12, 2025.

IMMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($257M) has a higher market cap than IMMP($238M). IMMP YTD gains are higher at: -25.806 vs. ARCT (-44.107). IMMP has higher annual earnings (EBITDA): -43.83M vs. ARCT (-77.4M). ARCT has more cash in the bank: 237M vs. IMMP (159M). IMMP has less debt than ARCT: IMMP (1.69M) vs ARCT (28.6M). ARCT has higher revenues than IMMP: ARCT (138M) vs IMMP (0).
ARCTIMMPARCT / IMMP
Capitalization257M238M108%
EBITDA-77.4M-43.83M177%
Gain YTD-44.107-25.806171%
P/E RatioN/AN/A-
Revenue138M0-
Total Cash237M159M149%
Total Debt28.6M1.69M1,697%
FUNDAMENTALS RATINGS
ARCT vs IMMP: Fundamental Ratings
ARCT
IMMP
OUTLOOK RATING
1..100
5653
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
9583
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for IMMP (84) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than IMMP’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as IMMP (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to IMMP’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as IMMP (96) in the Biotechnology industry. This means that ARCT’s stock grew similarly to IMMP’s over the last 12 months.

IMMP's Price Growth Rating (83) in the Biotechnology industry is in the same range as ARCT (95) in the Pharmaceuticals Major industry. This means that IMMP’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as IMMP (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to IMMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTIMMP
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 17 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 1 day ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TILRX25.59N/A
N/A
Nuveen Large Cap Growth R
FIICX16.58N/A
N/A
Fidelity Advisor Mid Cap II C
GMXRX14.74N/A
N/A
Nationwide Mid Cap Market Idx R
SVXCX53.92N/A
N/A
Smead International Value C
PAHWX7.66N/A
N/A
PGIM Jennison Intl Sm-Md Cap Opps A

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with BMEA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-7.01%
BMEA - ARCT
51%
Loosely correlated
-9.72%
AXON - ARCT
49%
Loosely correlated
-3.35%
ABCL - ARCT
47%
Loosely correlated
-5.86%
TRDA - ARCT
46%
Loosely correlated
-8.86%
BNTX - ARCT
42%
Loosely correlated
-1.40%
More